AbbVie’s hepatitis C treatment shows promise November 11, 2016 Drugmaker AbbVie Inc said on Friday its experimental fixed-dose combination to treat certain hepatitis C virus patients achieved high sustained viral response (SVR) rates after eight weeks of treatment.